Rising input costs, export slump take a toll on drug companies’ health
New Delhi: India's pharmaceutical industry is grappling with a twin challenge: rising input costs driven by a weakening rupee and sluggish export demand amid a global economic slowdown. The sharp appreciation of the US dollar against the rupee has pushed up the cost of raw materials, including active pharmaceutical ingredients (APIs) and key chemical intermediates. "Very true, the input cost…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
